{
  "symbol": "PFE",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1891,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.166
  },
  "top_positive": [
    {
      "sent": "2022 Form 10-K 1 potential need for and impact of additional equity or debt financing to pursue these opportunities, which could result in increased leverage and/or a downgrade of our credit ratings; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain acquired products; significant transaction costs; and unknown liabilities; \u2022 competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates; \u2022 the ability to successfully market both new and existing products, including biosimilars; \u2022 difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions; \u2022 the impact of public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&D and clinical trials; \u2022 risks and uncertainties related to our efforts to continue to develop and commercialize Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments, as well as challenges related to their manufacturing, supply and distribution; \u2022 risks related to our ability to achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments, including, among other things, whether and when additional supply or purchase agreements will be reached and the risk that demand for any products may be reduced, no longer exist or not meet expectations, which may lead to excess inventory on-hand and/or in the channel or reduced revenues; \u2022 trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; \u2022 interest rate and for\nactivities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; risks associated with preliminary, early stage or interim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; and whether and when additional data from our pipeline programs will be published in scientific journal publications, and if so, when and with what modifications and interpretations; \u2022 our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all; regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; the impact of, or uncertainties regarding the ability to obtain, recommendations by technical or advisory committees; and the timing of pricing approvals and product launches; \u2022 claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential, including uncertainties regarding the commercial or other impact of the results of the Xeljanz ORAL Surveillance (A3921133) study or actions by regulatory authorities based on analysis of ORAL Surveillance or other data, including on other JAK inhibitors in our portfolio; \u2022 the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the Pfizer Inc.",
      "score": 0.9933
    },
    {
      "sent": "2022 Form 10-K 3 The changes include establishing a new commercial structure within Biopharma, optimizing our end-to-end R&D operations and further prioritizing our internal R&D portfolio, as well as realigning certain enabling and platform functions across the organization to ensure alignment with this new operating structure, which is designed to better support and optimize performance across three broad customer groups as follows: Customer Groups Description Key Products Primary Care Includes: \u2022 Former Internal Medicine product portfolio (innovative brands in cardiovascular metabolic, migraine and women\u2019s health, as well as regional brands) \u2022 Former Vaccines product portfolio (innovative vaccines across all ages with a pipeline focus on infectious diseases with significant unmet medical need) \u2022 Products for COVID-19 prevention and treatment, and potential future mRNA and antiviral products \u2022 Eliquis, Nurtec ODT/Vydura and the Premarin family \u2022 The Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba \u2022 Comirnaty \u2022 Paxlovid Specialty Care Includes: \u2022 Former Inflammation & Immunology product portfolio (innovative brands and biosimilars for chronic immune and inflammatory diseases) \u2022 Former Rare Disease product portfolio (innovative brands for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia, endocrine diseases and sickle cell disease) \u2022 Former Hospital portfolio (global portfolio of sterile injectable and anti-infective medicines, excluding Paxlovid) \u2022 Xeljanz, Enbrel (outside the U.S.",
      "score": 0.9806
    },
    {
      "sent": "2022 Form 10-K 3 The changes include establishing a new commercial structure within Biopharma, optimizing our end-to-end R&D operations and further prioritizing our internal R&D portfolio, as well as realigning certain enabling and platform functions across the organization to ensure alignment with this new operating structure, which is designed to better support and optimize performance across three broad customer groups as follows: Customer Groups Description Key Products Primary Care Includes: \u2022 Former Internal Medicine product portfolio (innovative brands in cardiovascular metabolic, migraine and women\u2019s health, as well as regional brands) \u2022 Former Vaccines product portfolio (innovative vaccines across all ages with a pipeline focus on infectious diseases with significant unmet medical need) \u2022 Products for COVID-19 prevention and treatment, and potential future mRNA and antiviral products \u2022 Eliquis, Nurtec ODT/Vydura and the Premarin family \u2022 The Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba \u2022 Comirnaty \u2022 Paxlovid Specialty Care Includes: \u2022 Former Inflammation & Immunology product portfolio (innovative brands and biosimilars for chronic immune and inflammatory diseases) \u2022 Former Rare Disease product portfolio (innovative brands for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia, endocrine diseases and sickle cell disease) \u2022 Former Hospital portfolio (global portfolio of sterile injectable and anti-infective medicines, excluding Paxlovid) \u2022 Xeljanz, Enbrel (outside the U.S.",
      "score": 0.9806
    }
  ],
  "top_negative": [
    {
      "sent": "Failure by one or more of the third-party collaborators, service providers and others to complete activities on schedule or in accordance with our expectations or to meet their contractual or other obligations to us; failure of one or more of these parties to comply with applicable laws or regulations; disruptions in one or more of these parties\u2019 businesses, including unexpected demand for or shortage of raw materials or components, cyber-attacks on supplier systems, labor disputes or shortage and inclement weather, as well as natural or man-made disasters or pandemics; or any disruption in the relationships between us and these parties, could delay or prevent the development, approval, manufacturing or commercialization of our products and product candidates, expose us to suboptimal quality of service delivery or deliverables, result in repercussions such as missed deadlines or other timeliness issues, erroneous data and supply disruptions, and could also result in non-compliance with legal or regulatory requirements or industry standards or subject us to reputational harm, all with potential negative implications for our product pipeline and business.",
      "score": -0.9718
    },
    {
      "sent": "Failure by one or more of the third-party collaborators, service providers and others to complete activities on schedule or in accordance with our expectations or to meet their contractual or other obligations to us; failure of one or more of these parties to comply with applicable laws or regulations; disruptions in one or more of these parties\u2019 businesses, including unexpected demand for or shortage of raw materials or components, cyber-attacks on supplier systems, labor disputes or shortage and inclement weather, as well as natural or man-made disasters or pandemics; or any disruption in the relationships between us and these parties, could delay or prevent the development, approval, manufacturing or commercialization of our products and product candidates, expose us to suboptimal quality of service delivery or deliverables, result in repercussions such as missed deadlines or other timeliness issues, erroneous data and supply disruptions, and could also result in non-compliance with legal or regulatory requirements or industry standards or subject us to reputational harm, all with potential negative implications for our product pipeline and business.",
      "score": -0.9718
    },
    {
      "sent": "2022 Form 10-K 37 The following provides information about additional indications and new drug candidates in late-stage development: PRODUCT/CANDIDATE PROPOSED INDICATION LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS Ibrance (palbociclib) (a) ER+/HER2+ metastatic breast cancer Xtandi (enzalutamide) (b) Non-metastatic high-risk castration sensitive prostate cancer Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for first-line mCRPC Combination with Xtandi (enzalutamide) for DNA Damage Repair (DDR)-deficient mCSPC PF-06482077 (Vaccine) Immunization to prevent invasive and non-invasive pneumococcal infections (pediatric) somatrogon (PF-06836922) (c) Adult growth hormone deficiency Braftovi (encorafenib) and Erbitux \u00ae (cetuximab) (d) First-line BRAF V600E -mutant mCRC Braftovi (encorafenib) and Mektovi (binimetinib) and Keytruda \u00ae (pembrolizumab) (e) BRAF V600E/K -mutant metastatic or unresectable locally advanced melanoma Braftovi (encorafenib) and Mektovi (binimetinib) BRAF V600E -mutant non-small cell lung cancer Paxlovid (nirmatrelvir [PF-07321332]; ritonavir) COVID-19 in high-risk children (6-11 years of age; >88lbs) zavegepant (oral) Prevention of acute migraine (adults) ritlecitinib (PF-06651600) Vitiligo elranatamab (PF-06863135) Multiple myeloma double-class exposed Newly diagnosed multiple myeloma post-transplant maintenance Eliquis (apixaban) Venous thromboembolism (pediatric) NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT aztreonam-avibactam (PF-06947387) Treatment of infections caused by Gram-negative bacteria with limited or no treatment options fidanacogene elaparvovec (PF-06838435) (f) Hemophilia B giroctocogene fitelparvovec (PF-07055480) (g) Hemophilia A PF-06425090 (Vaccine) Immunization to prevent primary clostridioides difficile infection sasanlimab (PF-06801591) Combination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer fordadistrogene movaparvovec (PF-06939926) Duchenne muscular dystrophy (ambulatory) marstacimab (PF-06741086) Hemophilia Omicron-based mRNA vaccine (h) Immunization to prevent COVID-19 (adults) VLA15 (PF-07307405) vaccine (i) Immunization to prevent Lyme Disease PF-07252220 (quadrivalent mRNA-based vaccine) Immunization to prevent influenza inclacumab (PF-07940370) Sickle Cell Disease (a) Being developed in collaboration with The Alliance Foundation Trials, LLC.",
      "score": -0.9686
    }
  ],
  "forward_snippets": [
    "We also have a Pfizer Investor Insights website, which includes articles on the company, its products and its pipeline, located at insights.pfizer.com .",
    "We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001-2192.",
    "We will disclose any future amendments to, or waivers from, provisions of the Pfizer Policies on Business Conduct affecting our Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and executive officers on our website as promptly as practicable, as may be required under applicable SEC and NYSE rules.",
    "We also have a Pfizer Investor Insights website, which includes articles on the company, its products and its pipeline, located at insights.pfizer.com .",
    "We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001-2192."
  ]
}